FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

Uloženo v:
Podrobná bibliografie
Vydáno v:Nucleic acid therapeutics Ročník 27; číslo 1; s. 1 - 3
Hlavní autoři: Aartsma-Rus, Annemieke, Krieg, Arthur M.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Los Angeles, CA Mary Ann Liebert, Inc 01.02.2017
SAGE Publications
Témata:
ISSN:2159-3337, 2159-3345, 2159-3345
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Author Krieg, Arthur M.
Aartsma-Rus, Annemieke
Author_xml – sequence: 1
  givenname: Annemieke
  surname: Aartsma-Rus
  fullname: Aartsma-Rus, Annemieke
  organization: 1Leiden University Medical Center, Leiden, the Netherlands
– sequence: 2
  givenname: Arthur M.
  surname: Krieg
  fullname: Krieg, Arthur M.
  organization: 2Checkmate Pharmaceuticals, Cambridge, Massachusetts
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27929755$$D View this record in MEDLINE/PubMed
BookMark eNqNkUFvFCEYhompsbX26NVwNCa7AgPD4MFks23VpOrBekaG-WaHZhZGYBr33zuT3TbVpFEukI-Hhzd5n6MjHzwg9JKSJSWVeutNXjJCyyUphXyCThgValEUXBzdnwt5jM5SuiHTEoTwSjxDx0wqpqQQJ-jH5fkKr4YhhltI-CLD0LuYwOM2RHw-2g68B_x5THbszTTZpRzD0O3e4esO8Bf4lfG6M0OGiJ3HeZo9cHwzG_MCPW1Nn-DssJ-i75cX1-uPi6uvHz6tV1cLK0qRF8CYEg1XlnMKFbGNUbJivCWlMnVjJRcFJ6JmvOa2ZA1jraEt5RKErIgxVXGK3u-9w1hvobHgczS9HqLbmrjTwTj95413nd6EWy0KynhJJsHrgyCGnyOkrLcuWeh74yGMSdNKsoozzuR_oFxWSlLFJvTVw1j3ee4amIBiD9gYUorQauuyyS7MKV2vKdFz1XqqWs9V67nq6dXir1d34sf4N3s-mQ3omzBGP5XxKHyINAuN972DGmL-xxe_AdheyR4
CitedBy_id crossref_primary_10_3390_ijms26146742
crossref_primary_10_1007_s11940_018_0509_2
crossref_primary_10_1016_j_nmd_2018_06_009
crossref_primary_10_3233_JND_210743
crossref_primary_10_3390_cells9010137
crossref_primary_10_3390_ph14111113
crossref_primary_10_1016_j_ijpharm_2017_08_116
crossref_primary_10_1016_j_ymthe_2017_07_014
crossref_primary_10_3390_ijms23052736
crossref_primary_10_3390_pharmaceutics17010104
crossref_primary_10_1007_s12274_018_2131_8
crossref_primary_10_1186_s40246_025_00811_z
crossref_primary_10_3233_JND_221648
crossref_primary_10_1002_mgg3_1664
crossref_primary_10_1242_dmm_041673
crossref_primary_10_1016_j_omtn_2017_06_013
crossref_primary_10_1016_j_biopha_2024_116737
crossref_primary_10_1111_gtc_12730
crossref_primary_10_1016_j_omtn_2018_04_004
crossref_primary_10_1111_raq_12712
crossref_primary_10_1038_s41417_021_00324_6
crossref_primary_10_1089_nat_2020_0907
crossref_primary_10_3389_fphar_2022_950651
crossref_primary_10_1261_rna_071290_119
crossref_primary_10_1002_jgm_3015
crossref_primary_10_3390_children4090082
crossref_primary_10_1016_j_ymthe_2018_10_011
crossref_primary_10_1016_j_ymthe_2020_03_003
crossref_primary_10_1038_s41467_018_06206_0
crossref_primary_10_1016_j_bioactmat_2022_05_016
crossref_primary_10_1089_nat_2018_0759
crossref_primary_10_1089_nat_2018_0756
crossref_primary_10_1093_glycob_cwab115
crossref_primary_10_1080_00498254_2022_2115428
crossref_primary_10_1136_bmjopen_2019_029341
crossref_primary_10_1016_j_nmd_2018_02_013
crossref_primary_10_1016_j_tet_2019_130914
crossref_primary_10_1111_cpr_12599
crossref_primary_10_1038_s41401_020_00515_1
crossref_primary_10_1007_s00439_017_1790_y
crossref_primary_10_1038_s41398_023_02356_y
crossref_primary_10_1038_gt_2017_29
crossref_primary_10_1016_j_chembiol_2023_09_005
crossref_primary_10_1016_j_jconrel_2017_04_037
crossref_primary_10_1097_MNH_0000000000000586
crossref_primary_10_3390_biomedicines10010158
crossref_primary_10_1038_s41598_020_80495_8
crossref_primary_10_1002_jimd_12251
crossref_primary_10_1002_humu_23659
crossref_primary_10_1186_s13023_023_02767_6
crossref_primary_10_1016_j_gene_2023_147358
crossref_primary_10_3390_ijms25020761
crossref_primary_10_1089_hum_2020_034
crossref_primary_10_1186_s13023_019_1069_6
crossref_primary_10_1007_s40259_024_00665_2
crossref_primary_10_3390_biomedicines5030045
crossref_primary_10_1016_j_cotox_2019_09_004
crossref_primary_10_1093_hmg_ddy018
crossref_primary_10_1186_s40478_020_00918_5
crossref_primary_10_1016_j_omtn_2022_03_011
crossref_primary_10_1038_s42003_024_06121_9
crossref_primary_10_1371_journal_pone_0213649
crossref_primary_10_1155_2017_8765154
crossref_primary_10_1016_j_tips_2018_03_003
crossref_primary_10_1016_j_bbagrm_2019_06_006
crossref_primary_10_1177_22143602251317422
crossref_primary_10_3390_cells12111523
crossref_primary_10_3389_fmed_2022_859930
crossref_primary_10_1016_j_omtn_2019_02_024
crossref_primary_10_1080_14712598_2021_1832462
crossref_primary_10_1021_acschembio_4c00608
crossref_primary_10_1080_17512433_2019_1634543
crossref_primary_10_1073_pnas_2425659122
crossref_primary_10_1089_cmb_2019_0167
crossref_primary_10_1016_j_omtn_2017_07_006
crossref_primary_10_1016_j_lssr_2022_08_006
crossref_primary_10_1016_j_mam_2021_101003
crossref_primary_10_1093_nar_gkx1239
crossref_primary_10_1016_j_omtn_2025_102665
crossref_primary_10_1146_annurev_pharmtox_010818_021712
crossref_primary_10_1007_s13311_021_01137_z
crossref_primary_10_3390_cancers15112918
crossref_primary_10_1016_j_ijpharm_2024_124435
crossref_primary_10_3233_JND_210678
crossref_primary_10_1016_j_ymthe_2020_12_023
crossref_primary_10_1016_j_ymthe_2020_12_022
crossref_primary_10_1089_nat_2017_0665
crossref_primary_10_1016_j_omtm_2020_01_003
crossref_primary_10_1016_j_resp_2019_01_009
crossref_primary_10_1158_1541_7786_MCR_22_0541
crossref_primary_10_1177_22143602251324858
crossref_primary_10_1016_j_annonc_2022_03_011
crossref_primary_10_1080_17460441_2018_1546286
crossref_primary_10_1039_D4MD00394B
crossref_primary_10_1038_s41573_023_00775_6
crossref_primary_10_1038_s41598_021_82725_z
crossref_primary_10_3390_jpm7040013
crossref_primary_10_1016_j_jns_2021_117337
crossref_primary_10_1016_j_tips_2018_09_001
crossref_primary_10_1038_s41467_019_12335_x
crossref_primary_10_1038_s41582_018_0033_8
crossref_primary_10_1007_s12038_023_00411_w
crossref_primary_10_1177_10742484221088655
crossref_primary_10_1038_s41434_020_00197_8
crossref_primary_10_1002_adtp_202100040
crossref_primary_10_1016_j_jddst_2018_04_001
crossref_primary_10_1002_jcp_30311
crossref_primary_10_1080_15476286_2025_2503040
crossref_primary_10_1038_s41556_020_00595_5
crossref_primary_10_1186_s43556_022_00077_0
crossref_primary_10_1089_nat_2017_0682
crossref_primary_10_1172_JCI152079
crossref_primary_10_3390_ijms23094824
crossref_primary_10_3390_genes8020067
crossref_primary_10_36290_neu_2020_119
crossref_primary_10_1089_nat_2024_0085
crossref_primary_10_1007_s40259_023_00632_3
crossref_primary_10_1016_j_brainres_2020_146683
crossref_primary_10_1124_pr_120_019554
crossref_primary_10_3390_cells13080666
crossref_primary_10_1016_j_omtn_2018_06_005
crossref_primary_10_1146_annurev_med_041217_010829
crossref_primary_10_1016_j_nmd_2018_08_012
crossref_primary_10_1089_nat_2020_0860
crossref_primary_10_1007_s00415_024_12485_z
crossref_primary_10_1089_nat_2020_0862
crossref_primary_10_1016_j_ymthe_2017_02_019
crossref_primary_10_1016_j_jconrel_2020_10_029
crossref_primary_10_1186_s13099_023_00545_0
crossref_primary_10_3390_ph15080909
crossref_primary_10_1134_S1068162021020175
crossref_primary_10_1016_j_ppedcard_2021_101460
crossref_primary_10_3390_antibiotics13030221
crossref_primary_10_3390_cells12182253
crossref_primary_10_1371_journal_pcbi_1008605
crossref_primary_10_1089_nat_2022_0063
crossref_primary_10_1038_nrcardio_2017_190
crossref_primary_10_1016_j_ymthe_2024_10_024
crossref_primary_10_1126_science_aau1549
crossref_primary_10_1016_j_actbio_2020_10_009
crossref_primary_10_1016_j_omtn_2018_10_004
crossref_primary_10_3390_biom13091319
crossref_primary_10_1016_j_ymthe_2025_04_038
crossref_primary_10_1242_dmm_040832
crossref_primary_10_3390_life12050608
crossref_primary_10_1016_j_jconrel_2019_11_025
crossref_primary_10_15252_emmm_201607199
crossref_primary_10_3233_JND_200560
crossref_primary_10_1111_gtc_12587
crossref_primary_10_1038_cgt_2017_27
crossref_primary_10_3389_fnmol_2024_1391564
crossref_primary_10_1016_j_yjmcc_2018_10_008
crossref_primary_10_1111_nan_12448
crossref_primary_10_1186_s13023_018_0853_z
crossref_primary_10_1016_j_mehy_2017_11_009
crossref_primary_10_3390_jcm7090291
crossref_primary_10_3390_jcm9062004
crossref_primary_10_1016_j_omtn_2017_12_004
crossref_primary_10_1002_jcsm_12231
crossref_primary_10_1089_nat_2023_0027
crossref_primary_10_1002_acn3_51933
crossref_primary_10_1007_s00439_017_1789_4
crossref_primary_10_1016_j_nantod_2019_02_005
crossref_primary_10_1016_j_phrs_2020_104917
crossref_primary_10_1080_14712598_2017_1271872
crossref_primary_10_1016_j_cobme_2024_100523
crossref_primary_10_1089_nat_2019_0835
crossref_primary_10_3390_cells12151952
crossref_primary_10_1126_scitranslmed_aan8081
crossref_primary_10_1016_j_ebiom_2019_06_036
crossref_primary_10_3390_genes13010109
crossref_primary_10_1016_j_mencom_2019_03_017
crossref_primary_10_1007_s12325_019_00920_x
crossref_primary_10_3390_ijms26010300
crossref_primary_10_3390_ijms25042007
crossref_primary_10_12688_f1000research_16106_1
crossref_primary_10_3390_biomedicines8090332
crossref_primary_10_1016_j_npep_2023_102356
crossref_primary_10_3390_genes16020185
crossref_primary_10_2217_nnm_2021_0224
crossref_primary_10_3390_jcm14155515
crossref_primary_10_1002_acn3_51149
crossref_primary_10_1007_s00439_017_1792_9
crossref_primary_10_1016_j_omtn_2019_09_012
crossref_primary_10_1016_j_taap_2018_12_009
crossref_primary_10_1089_nat_2019_0824
crossref_primary_10_3390_molecules26175420
crossref_primary_10_1089_gtmb_2020_0246
crossref_primary_10_1146_annurev_pathmechdis_012418_012945
crossref_primary_10_1007_s11136_018_1891_7
crossref_primary_10_1093_hmg_ddy171
crossref_primary_10_1016_j_nmd_2018_05_013
crossref_primary_10_1038_s41582_019_0203_3
crossref_primary_10_1007_s00125_023_05960_1
crossref_primary_10_1016_j_ymthe_2018_01_021
crossref_primary_10_1016_j_omtn_2017_09_006
crossref_primary_10_3390_genes9090455
crossref_primary_10_1016_j_neuron_2019_01_056
crossref_primary_10_1002_chem_201701670
crossref_primary_10_3390_molecules29112658
crossref_primary_10_1097_CM9_0000000000000542
crossref_primary_10_1186_s12910_020_0463_x
crossref_primary_10_1371_journal_pone_0204485
crossref_primary_10_1038_s41598_017_17982_y
crossref_primary_10_1002_wrna_1653
crossref_primary_10_1016_j_copbio_2017_12_001
crossref_primary_10_1038_s41467_022_31636_2
crossref_primary_10_3390_genes15111489
crossref_primary_10_3390_ijms20092067
crossref_primary_10_1007_s40271_018_0311_y
crossref_primary_10_3390_cells12081110
crossref_primary_10_1261_rna_075028_120
crossref_primary_10_3390_genes11080837
crossref_primary_10_1007_s40141_019_00255_2
crossref_primary_10_1016_j_addr_2021_113834
crossref_primary_10_1161_CIRCULATIONAHA_117_028382
crossref_primary_10_1002_acn3_51046
crossref_primary_10_3390_genes13112021
crossref_primary_10_1016_j_addr_2022_114564
crossref_primary_10_3389_fneur_2018_00009
crossref_primary_10_1007_s10072_022_06085_w
crossref_primary_10_1016_j_omton_2024_200908
crossref_primary_10_3389_fphar_2021_735912
crossref_primary_10_1097_HCO_0000000000001210
crossref_primary_10_1089_nat_2020_0845
crossref_primary_10_1016_j_ijpharm_2021_120398
crossref_primary_10_12688_f1000research_16422_1
crossref_primary_10_1371_journal_pone_0197084
crossref_primary_10_1007_s00424_019_02272_5
crossref_primary_10_1016_j_omtn_2019_09_020
crossref_primary_10_3390_ijms21239032
crossref_primary_10_1186_s13100_024_00320_1
crossref_primary_10_4103_1673_5374_385285
crossref_primary_10_1016_j_pharmthera_2018_11_011
crossref_primary_10_3390_ijms26031303
crossref_primary_10_1093_bmb_ldad010
crossref_primary_10_12688_wellcomeopenres_18251_1
crossref_primary_10_1016_j_biomaterials_2019_119416
crossref_primary_10_3389_fphar_2023_1304342
Cites_doi 10.1002/ana.24555
10.1371/journal.pone.0161955
10.1002/ana.23982
10.1016/S1474-4422(16)30035-7
ContentType Journal Article
Copyright Annemieke Aartsma-Rus, et al., 2017; Published by Mary Ann Liebert, Inc.
Annemieke Aartsma-Rus, et al., 2017; Published by Mary Ann Liebert, Inc. 2017
Copyright_xml – notice: Annemieke Aartsma-Rus, et al., 2017; Published by Mary Ann Liebert, Inc.
– notice: Annemieke Aartsma-Rus, et al., 2017; Published by Mary Ann Liebert, Inc. 2017
DBID 1-M
AFRWT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7TM
5PM
DOI 10.1089/nat.2016.0657
DatabaseName Mary Ann Liebert Online - Open Access
Sage Journals GOLD Open Access 2024
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Nucleic Acids Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Nucleic Acids Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2159-3345
EndPage 3
ExternalDocumentID PMC5312460
27929755
10_1089_nat_2016_0657
10.1089_nat.2016.0657
Genre Journal Article
GroupedDBID ---
-IN
0R~
1-M
3V.
4.4
53G
7X7
88A
88E
88I
8C1
8FE
8FH
8FI
8FJ
ABBKN
ABJNI
ABUWG
ACGFS
ACGOD
ACPRK
ADBBV
AENEX
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BBNVY
BENPR
BHPHI
BNQNF
BPHCQ
BVXVI
CCPQU
DWQXO
EBS
EJD
FYUFA
GNUQQ
HCIFZ
HMCUK
IM4
LK8
M0L
M1P
M2P
M7P
O9-
PQQKQ
PROAC
PSQYO
RML
UE5
UKHRP
AEUYN
AFFHD
AFRWT
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
SCNPE
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
PUEGO
7TM
5PM
ID FETCH-LOGICAL-c565t-e2295d49c441e80cda97824f069abdc7453405b24b4c62d22fa1f147e5780aa83
ISICitedReferencesCount 297
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000393777800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2159-3337
2159-3345
IngestDate Tue Nov 04 01:53:54 EST 2025
Wed Oct 01 15:01:57 EDT 2025
Sun Aug 24 03:32:13 EDT 2025
Thu Jan 02 23:11:57 EST 2025
Tue Nov 18 22:03:41 EST 2025
Sat Nov 29 07:29:11 EST 2025
Sun Nov 09 05:59:39 EST 2025
Fri Sep 27 01:23:10 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords splicing modulation
therapy
regulatory
oligonucleotide
Language English
License This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
http://www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c565t-e2295d49c441e80cda97824f069abdc7453405b24b4c62d22fa1f147e5780aa83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC5312460
PMID 27929755
PQID 1847897192
PQPubID 23479
PageCount 3
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5312460
proquest_miscellaneous_1872842427
proquest_miscellaneous_1847897192
pubmed_primary_27929755
crossref_citationtrail_10_1089_nat_2016_0657
crossref_primary_10_1089_nat_2016_0657
sage_journals_10_1089_nat_2016_0657
maryannliebert_primary_10_1089_nat_2016_0657
PublicationCentury 2000
PublicationDate 20170201
2017-02-00
PublicationDateYYYYMMDD 2017-02-01
PublicationDate_xml – month: 02
  year: 2017
  text: 20170201
  day: 01
PublicationDecade 2010
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: United States
– name: 140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA
PublicationTitle Nucleic acid therapeutics
PublicationTitleAlternate Nucleic Acid Ther
PublicationYear 2017
Publisher Mary Ann Liebert, Inc
SAGE Publications
Publisher_xml – name: Mary Ann Liebert, Inc
– name: SAGE Publications
References Mendell, Rodino-Klapac, Sahenk, Roush, Bird, Lowes, Alfano, Gomez, Lewis 2013; 74
Straub, Balabanov, Bushby, Ensini, Goemans, De Luca, Pereda, Hemmings, Campion 2016; 15
Goemans, Tulinius, van den Hauwe, Kroksmark, Buyse, Wilson, van Deutekom, de Kimpe, Lourbakos, Campion 2016; 11
Mendell, Goemans, Lowes, Alfano, Berry, Shao, Kaye, Mercuri 2016; 79
B2
B4
B7
B14
26573217 - Ann Neurol. 2016 Feb;79(2):257-71
23907995 - Ann Neurol. 2013 Nov;74(5):637-47
27302365 - Lancet Neurol. 2016 Jul;15(8):882-90
27588424 - PLoS One. 2016 Sep 02;11(9):e0161955
References_xml – volume: 79
  start-page: 257
  year: 2016
  end-page: 271
  article-title: Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
  publication-title: Ann Neurol
– volume: 74
  start-page: 637
  year: 2013
  end-page: 647
  article-title: Eteplirsen for the treatment of Duchenne muscular dystrophy
  publication-title: Ann Neurol
– volume: 15
  start-page: 882
  year: 2016
  end-page: 890
  article-title: Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
  publication-title: Lancet Neurol
– volume: 11
  start-page: e0161955
  year: 2016
  article-title: Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study
  publication-title: PLoS One
– ident: B7
  doi: 10.1002/ana.24555
– ident: B2
  doi: 10.1371/journal.pone.0161955
– ident: B4
  doi: 10.1002/ana.23982
– ident: B14
  doi: 10.1016/S1474-4422(16)30035-7
– reference: 23907995 - Ann Neurol. 2013 Nov;74(5):637-47
– reference: 27588424 - PLoS One. 2016 Sep 02;11(9):e0161955
– reference: 27302365 - Lancet Neurol. 2016 Jul;15(8):882-90
– reference: 26573217 - Ann Neurol. 2016 Feb;79(2):257-71
SSID ssj0000500485
Score 2.5990624
SecondaryResourceType review_article
SourceID pubmedcentral
proquest
pubmed
crossref
sage
maryannliebert
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1
SubjectTerms Adolescent
Child
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Approval
Dystrophin - genetics
Exons
Humans
Issues in Development
Morpholinos - therapeutic use
Muscular Dystrophy, Duchenne - drug therapy
Muscular Dystrophy, Duchenne - economics
Oligonucleotides - therapeutic use
Time Factors
Treatment Outcome
United States
United States Food and Drug Administration
Walk Test
Young Adult
Title FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
URI https://www.liebertpub.com/doi/abs/10.1089/nat.2016.0657
https://journals.sagepub.com/doi/full/10.1089/nat.2016.0657
https://www.ncbi.nlm.nih.gov/pubmed/27929755
https://www.proquest.com/docview/1847897192
https://www.proquest.com/docview/1872842427
https://pubmed.ncbi.nlm.nih.gov/PMC5312460
Volume 27
WOSCitedRecordID wos000393777800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2159-3345
  dateEnd: 20181231
  omitProxy: false
  ssIdentifier: ssj0000500485
  issn: 2159-3337
  databaseCode: M7P
  dateStart: 20030801
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2159-3345
  dateEnd: 20181231
  omitProxy: false
  ssIdentifier: ssj0000500485
  issn: 2159-3337
  databaseCode: 7X7
  dateStart: 20030801
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2159-3345
  dateEnd: 20181231
  omitProxy: false
  ssIdentifier: ssj0000500485
  issn: 2159-3337
  databaseCode: BENPR
  dateStart: 20030801
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 2159-3345
  dateEnd: 20181231
  omitProxy: false
  ssIdentifier: ssj0000500485
  issn: 2159-3337
  databaseCode: 8C1
  dateStart: 20030801
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 2159-3345
  dateEnd: 20181231
  omitProxy: false
  ssIdentifier: ssj0000500485
  issn: 2159-3337
  databaseCode: M2P
  dateStart: 20030801
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lc9MwENbQlgMHGKA8wiMjBiYX6tZv2dxCkwyHNGRKOpObkW2FZiBO8INp_z27suzYQ4By4KJJbI1kez_vrqTPnwh544uQgWG5Frk81GwWhxrEHUuzITSgmrnPhdSZHbPJxJvP_amiBGVyOwGWJN7Vlb_5r6aGY2Bs_HT2H8xdNwoH4DcYHUowO5Q3Mvxo0MfcMl2jnuwwF5Blppko-YSDAmwEnvXtWaEIqIPrLE_X-KwV_WIC3hoX4TeonqhIkI1WPvEvvJnQTlAPGTVfo6VkYlYfc9Wpeh8uMVtx7bwo9z2G3ldL8bXGE3gZId1NP80vi1TNzqp5CIhtes3pkO4Kcgdfs6xSwuVYNI-VgpGVvy21AFq4Kp2n0YjC1k73rnuojppwJMEa7jGkT2wbx6q1-8nHYHQxHgez4XzW23zXcIcxXIlX263skQOTOb4naZ7Tej5Od9CZIeO1vhElyQqdnrS6bKUwd_ELQ54kMGJAJvyugcqvfNsGaVDmMbP75J4agNB-CZwH5JZIHpLDPnS9Xl3THpWUYLnWckg-A5ZohSW6RQEFLNEKS7TCEq2x9I4CkigiiSok0WVCAR3NNhBJj8jFaDg7_aCpLTm0CDL_XBO4-3ts-xFk0cLTo5j7kGLaC931eRhHzIY3XHdC0w7tyDVj01xwY2HYTEBg0Dn3rMdkP1kn4imhjmeF3LViOK_bCxbB0B_KyHMdEXJhmx1yVD3lIFJ69bhtyrdA8iY8P4AnE6BRAjRKh_Tq6ptSqOV3FY_aJvtb9VeVQQPwvLicxhOxLrLAgMTO88HTmX-qwyD_gzQY2nlSgqDuDqU7feY4HcJa8KgroPJ7-0yyvJQK8BA4TdvVO-Q1AilQ3ifbfQfPbnB1z8md7Tv9guznaSFektvRj3yZpV2yx-ZMlh6U3qnRJQfvh5PpOfw7M6dd-Sb9BJjW33E
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FDA+Approves+Eteplirsen+for+Duchenne+Muscular+Dystrophy%3A+The+Next+Chapter+in+the+Eteplirsen+Saga&rft.jtitle=Nucleic+acid+therapeutics&rft.au=Aartsma-Rus%2C+Annemieke&rft.au=Krieg%2C+Arthur+M&rft.date=2017-02-01&rft.issn=2159-3337&rft.eissn=2159-3345&rft.volume=27&rft.issue=1&rft.spage=1&rft.epage=3&rft_id=info:doi/10.1089%2Fnat.2016.0657&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2159-3337&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2159-3337&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2159-3337&client=summon